Infliximab therapy in pediatric crohn's disease: A review

Clinical and Experimental Gastroenterology

Volumn 3, Issue 1, 2010, Pages 57-63

  Parashette, Kalyan Ray ^a   Makam, Charan Raghavendra ^b   Cuffari, Carmen ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BERKSHIRE MEDICAL CENTER   (United States)

^c JOHNS HOPKINS CHILDREN S CENTER   (United States)

Author keywords

Crohn's disease; Infliximab; Pediatric

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL ABSCESS; ANUS FISTULA; ARTHRALGIA; BACKACHE; CELLULITIS; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; ENTERIC FEEDING; FLUSHING; GRANULOMA; HEPATITIS B; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; IMMUNOGENICITY; LATENT TUBERCULOSIS; LISTERIOSIS; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MYALGIA; NAUSEA; NEUTROPHIL COUNT; PARENTERAL NUTRITION; PNEUMONIA; PRURITUS; REMISSION; REVIEW; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SUPERINFECTION; T CELL LYMPHOMA; THORAX PAIN; TINEA; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS;

EID: 77955464751     PISSN: None     EISSN: 11787023     Source Type: Book Series    
DOI: None     Document Type: Review

References (59)

1. Cuffari C. Inflammatory bowel disease in children: A pediatrician's perspective. Minerva Pediatr. 2006;58(2):139-157.
2. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in wisconsin: A statewide population-based study. J Pediatr. 2003;143(4):525-531.
3. Hildebrand H, Finkel Y, Grahnquist L, et al. Changing pattern of paediatric inflammatory bowel disease in northern stockholm 1990-2001. Gut. 2003;52(10):1432-1434.
4. Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of children with crohn's disease. Gut. 1993;34(7):939-943.
5. Hiwatashi N. Enteral nutrition for crohn's disease in Japan. Dis Colon Rectum. 1997;40(10 Suppl):S48-S53.
6. Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active crohn's disease. Gastroenterology. 1995;108(4):1056-1067.
7. Gonzalez-Huix F, de Leon R, Fernandez-Banares F, et al. Polymeric enteral diets as primary treatment of active crohn's disease: A prospective steroid controlled trial. Gut. 1993;34(6):778-782.
8. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active crohn's disease. international budesonidemesalamine study group. N Engl J Med. 1998;339(6):370-374.
9. de Franchis R, Omodei P, Ranzi T, et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in crohn's disease. Aliment Pharmacol Ther. 1997;11(5):845-852.
10. Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2003;36(2):248-252.
11. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in crohn's disease. Gut. 1994;35(3): 360-362.
12. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active crohn's disease. canadian inflammatory bowel disease study group. N Engl J Med. 1994;331(13):836-841.
13. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active crohn's disease. N Engl J Med. 1994; 331(13):842-845.
14. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active crohn's disease. the global budesonide study group. Gut. 1997;41(2):209-214.
15. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of crohn's disease. Gut. 1995;37(5): 674-678.
16. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed crohn's disease. Gastroenterology. 2000;119(4):895-902.
17. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of crohn's disease. the north american crohn's study group investigators. N Engl J Med. 1995;332(5):292-297.
18. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in crohn's disease. North american crohn's study group investigators. N Engl J Med. 2000; 342(22):1627-1632.
19. Bell SJ, Kamm MA. Review article: The clinical role of anti-TNFalpha antibody treatment in crohn's disease. Aliment Pharmacol Ther. 2000; 14(5):501-514.
20. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and crohn's disease. Clin Exp Immunol. 1993;94(1):174-181.
21. Nicholls S, Stephens S, Braegger CP, et al. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol. 1993;46(8):757-760.
22. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with crohn's disease. Aliment Pharmacol Ther. 2001;15(4):463-473.
23. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121(5): 1145-1157.
24. Ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in crohn's disease. Gut. 2002;50(2):206-211.
25. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNFalpha and activates immune effector functions. Cytokine. 1995;7(3): 251-259.
26. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002; 359:1541-1549.
27. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for crohn disease. J Pediatr Gastroenterol Nutr. 2005;40(2): 220-222
28. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM study. Gastroenterology. 2007;132:52-55.
29. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
30. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric crohn's disease. Am J Gastroenterol. 2000;95(11):3189-3194.
31. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric crohn's disease. Aliment Pharmacol Ther. 2003;18(4):425-431.
32. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with crohn's disease. Dig Liver Dis. 2004;36(5):342-347.
33. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs. 2007;67(12): 1703-1723.
34. de Ridder L, Benninga MA, Taminiau JA, et al. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45(1):3-14.
35. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric crohn's disease. Am J Gastroenterol. 2003;98(4):833-838.
36. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2003;36(5):632-636.
37. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of crohn's disease in children and adolescents. J Pediatr. 2000;137(2): 192-196.
38. Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with crohn's disease. Inflamm Bowel Dis. 2004;10(6):745-750.
39. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132(3):863-873.
40. Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observation from REACH. J Pediatr Gastroenterol Nutr. 2009;49:183-190.
41. Ruemmele FM, Lachaux A, Cezard JP, et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multi-center open-label trial comparing schedule to on demand maintenance therapy. Inflamm Bowel Dis. 2009;15:388-394.
42. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009;15:816-822.
43. Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric crohn's disease. Clin Immunol. 2006;118(1):11-19.
44. Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38(5):502-508.
45. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in crohn's disease. N Engl J Med. 2003;348(7):601-608.
46. Friesen CA, Calabro C, Christenson K, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2004;39(3):265-269.
47. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive model. Aliment Pharmacol Ther. 2003;17(1):75-84.
48. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: Results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 2005;11(5):442-446.
49. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in crohn's disease: A prospective cohort study. Gastroenterology. 2003;125(1):32-39.
50. Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346(8):623-626.
51. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098-1104.
52. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs. 2007;67(12): 1703-1723.
53. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with crohn's disease: The mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19-31.
54. Kamath BM, Mamula P, Baldassano RN, et al. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr. 2002; 34(4):410-412.
55. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in crohn's disease patients: Need for primary prophylaxis. Gut. 2004;53(9):1363-1365.
56. Cezard JP, Nouaili N, Talbotec C, et al A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2003;36(5):632-636.
57. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621-630.
58. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in crohn's disease: A multicentre matched pair study. Gut. 2006;55(2):228-233.
59. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44(2):265-267.